[1] Aizpurua-Olaizola O, Elezgarai I, Rico-Barrio I, Zarandona I, Etxebarria N, Usobiaga A. Targeting the endocannabinoid system: future therapeutic strategies. Drug Discov Today. 2017 Jan;22(1):105-110. doi: 10.1016/j.drudis.2016.08.005. Epub 2016 Aug 20. PMID: 27554802.
[2] Console-Bram L, Marcu J, Abood ME. Cannabinoid receptors: nomenclature and pharmacological principles. Prog Neuropsychopharmacol Biol Psychiatry. 2012 Jul 2;38(1):4-15. doi: 10.1016/j.pnpbp.2012.02.009. Epub 2012 Feb 28. PMID: 22421596; PMCID: PMC3378782.
[3] Lutz B. Neurobiology of cannabinoid receptor signaling. Dialogues Clin Neurosci. 2020 Sep;22(3):207-222. doi: 10.31887/DCNS.2020.22.3/blutz. PMID: 33162764; PMCID: PMC7605026.
[4] Costa J, et al; Neurobiologia da Cannabis: do sistema endocanabinoide aos transtornos por uso de Cannabis. J Bras Psiquiatr. 2011;60(2):111-122.
[5] Ogawa S, Kunugi H; inhibitors of Fatty Acid Amide Hydrolase and Mono acylglycerol Lipase: New targets for future Antidepressants. Curremt Neuropharmacology, 2015;13:760-775.
[6] Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-60. doi: 10.2165/00003088-200342040-00003. PMID: 12648025.
[7] Bow EW, Rimoldi JM. The Structure-Function Relationships of Classical Cannabinoids: CB1/CB2 Modulation. Perspect Medicin Chem. 2016 Jun 28;8:17-39. doi: 10.4137/PMC.S32171. PMID: 27398024; PMCID: PMC4927043.
[8] Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008 Jan;153(2):199-215. doi: 10.1038/sj.bjp.0707442. Epub 2007 Sep 10. PMID: 17828291; PMCID: PMC2219532.
[9] Guerrero-Alba R, et al. Some Prospective Alternatives for Treating Pain: The Endocannabinoid System and Its Putative Receptors GPR18 and GPR55. Front. Pharmacol. 2019 9:1496.
[10] Lucas et al. Cannabis Significantly Reduces the Use of Prescription Opioids and Improves Quality of Life in Authorized Patients: Results of a Large Prospective Study. Pain Medicine. 2021, 727–739.
[11] Russo E, Hohmann A. Role of Cannabinoids in Pain Management. Comprehensive Treatment of Chronic Pain by Medical, Interventional, and Integrative Approaches. January 2015; pp.181-197.
[12] Kesner AJ and Lovinger DM. (2020) Cannabinoids, Endocannabinoids and Sleep. Front. Mol. Neurosci. 13:125. doi: 10.3389/fnmol.2020.00125.
[13] Vaughn L, et al. Endocannabinoid signalling: has it got rhythm? Br J Pharmacol. 2010 Jun; 160(3): 530–543.
[14] Martin EL, Strickland JC, Schlienz NJ, Munson J, Jackson H, Bonn-Miller MO and Vandrey R (2021) Antidepressant and Anxiolytic Effects of Medicinal Cannabis Use in an Observational Trial. Front. Psychiatry 12:729800. doi: 10.3389/fpsyt.2021.729800
[15] Bambico F, Gobbi G. The cannabinoid CB 1 receptor and the endocannabinoid anandamide: possible antidepressant targets. Expert Opin Ther Targets. 2008 Nov;12(11):1347-66.
[16] Sexton et al. A Cross-Sectional Survey of Medical Cannabis Users: Patterns of Use and Perceived Efficacy. Cannabis and Cannabinoid Research Volume 1.1, 2016 DOI: 10.1089/can.2016.0007.
[17] Landin et al. Reviewing the Role of the Endocannabinoid System in the Pathophysiology of Depression. Front. Pharmacol., 06 December 2021 DOI: 10.3389/fphar.2021.762738.
[18] Narouze and MacCallum. Cannabinoids and Pain. Springer Nature Switzerland. 2021 DOI: 10.1007/978-3-030-69186-8.
[19] Russo EB (2019) The Case for the Entourage Effect and Conventional Breeding of Clinical Cannabis: No “Strain,” No Gain. Front. Plant Sci. 9:1969. doi: 10.3389/ fpls.2018.01969.
